Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) reports on the Annual Meeting of Stockholders held on August 17, 2021. The company is an emerging growth company with no securities currently registered on an exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Outcomes
Stockholders voted on six key matters at the Annual Meeting:
- Director Election: Nickolay Kukekov was elected as the Class I director with 1,489,074,356 votes for and 132,633,361 withheld.
- Stock Incentive Plan: The 2021 Stock Incentive Plan was approved (1,330,655,868 for; 210,280,073 against).
- Reincorporation: Stockholders rejected the proposal to reincorporate from Delaware to Nevada (1,475,309,685 for; 141,960,148 against).
- Reverse Stock Split: Stockholders approved amendments to the Certificate of Incorporation authorizing a reverse stock split with a ratio between 1-for-20 and 1-for-4000. The Board retains discretion on the exact ratio and whether to execute the split (1,646,094,543 for; 396,247,894 against).
- Authorized Shares Reduction: Stockholders authorized the Board to reduce the number of authorized common shares in proportion to the reverse split (1,737,454,890 for; 298,463,554 against).
- Auditor Ratification: Friedman LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021 (1,933,578,874 for; 90,227,445 against).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the voting results. The primary contingency noted is the Board's future discretion to determine the specific ratio of the reverse stock split or to forego the split entirely.
Investor Verification Checklist
- Verify the final decision and specific ratio of the reverse stock split, as the Board has discretion to act within the 1-for-20 to 1-for-4000 range.
- Confirm the effective date of the reduction in authorized shares, if the reverse split is executed.
- Review the terms of the newly approved 2021 Stock Incentive Plan for potential dilution impacts.
- Monitor future filings for the implementation of the reincorporation rejection and any subsequent corporate structure changes.